Conclusion:
We aim to highlight a diagnostic approach towards a new clinical entity
of de Novo AML with BCR/ABL fusion gene described by WHO in 2016 from
CML with BCR/ABL gene which can be challenging in some clinical
scenarios. And we also emphasize the need for T315I mutation analysis
study in TKI resistant cases of CML to deliver optimum patient care.